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Peripheral Neuropathy in 
Connective Tissue Diseases
Mouna Snoussi, Faten Frikha and Zouhir Bahloul
Abstract
Connective tissue diseases are characterized by different organ disorders due to 
loss of immune system tolerance to autoantigens. Peripheral neuropathy is one of the 
features of these diseases with variable frequency; it is more prevalent in Sjögren syn-
drome. Peripheral neuropathy is often seen in the course of the disease. Nonetheless, 
it may be also a presenting sign or the unique feature of immune system dysfunction. 
Neuropathies in connective tissue diseases are related mainly to vasculitic disorder. It 
requires prompt diagnosis and treatment to improve its outcome. Peripheral neuropa-
thy in connective tissue diseases could be multifocal and asymmetric, or confluent 
and symmetrical. This chapter reviews the clinical, diagnostic and therapeutic fea-
tures of neuropathies associated with the common diffuse connective tissue diseases.
Keywords: peripheral neuropathy, vasculitis, connective tissue disease,  
treatment, electromyography, nerve biopsy
1. Introduction
Connective tissue diseases (CTDs) are defined as a group of acquired diseases 
resulting from persistent immune-mediated inflammation. They are generally the 
consequence of autoimmune dysregulation resulting in generation of autoreactive T 
cells or autoantibodies [1]. Immune disorders can affect any organ of the human body 
responsible for multisystem involvement. The CTDs classily include systemic lupus 
erythematosus (SLE), Sjögren syndrome (SS), systemic sclerosis (SSc), dermatomyosi-
tis and polymyositis (PM/DM), undifferentiated CTD (UTCD) and overlap syndromes 
such as mixed CTD (MCTD). Most clinicians do not include systemic necrotizing vas-
culitis, e.g. polyarteritis nodosa, Churg-Strauss syndrome and Wegener’s granuloma-
tosis in the category of CTD [1]. Peripheral neuropathies (PN) may complicate many 
different systemic autoimmune diseases. PN in CTD large clinical, histopathological 
and pathogenic spectrum [2]. We aim in this chapter to precise the epidemiology, 
the pathogenesis, the diagnosis and the treatment of neuropathies in CTD including 
systemic lupus erythematosus (SLE), Sjögren syndrome (SS), dermatomyositis and 
polymyositis (PM/DM), systemic sclerosis (SSc) and mixed CTD (MCTD).
2.  Epidemiology of peripheral neuropathy associated with connective 
tissue diseases and its topographic distribution
PN is one of the clinical features of CTD with variable frequency and prognosis. 
It is often seen in the course of the disease. However, it may also be a presenting 
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sign or the unique feature of immune system dysfunction [3]. The prevalence of 
PN is different in the literature series depending on the type of CTD and the means 
of diagnosis. The incidence of PN in SS is 10–60%, and many of these patients 
(40–93%) present with neuropathy as the sentinel symptom [4]. PN in SLE patients 
ranges from 25 to 50% based on electrodiagnostic studies. Curiously, the incidence 
drops to only 5% based on clinical criteria [5, 6]. Finally, PN is rarely associated 
with the other CTD, namely, SSc, MCTD, DM and PM [4].
PN refers to the part of a spinal nerve distal to the root and plexus. It is a damage 
or a disease affecting nerves [7–9]. Neuropathy affecting one nerve is called “mono-
neuropathy” and neuropathy affecting multiple nerves in the same areas on both 
sides of the body is named “symmetrical polyneuropathy”. When separate nerves in 
disparate areas of the body are affected, the neuropathy is called mononeuritis multi-
plex, multifocal mononeuropathy or multiple mononeuropathy [8, 10, 11]. Types of 
neuropathies that are associated with CTD are outlined in Table 1.
3. Pathogenesis of peripheral neuropathy in connective tissue diseases
The principal components in the pathogenesis of peripheral nerve lesions in 
diffuse CTD are ischemia due to vasculitis and immune abnormalities. Generally, 
most of patients have a combination of the ischemic, immunological and metabolic 
mechanisms of damage to the peripheral nervous system. Nevertheless, one com-
ponent may be predominant in a different stage of the disease. In systemic sclero-
derma, the greater role is played by ischemic mechanisms, mainly in the initial 
states of the disease, while SLE may involve the participation of immunological 
mechanisms, especially in acute and subacute disease with high level of autoim-
mune activity [13].
3.1 Vasculitic neuropathy
The immunopathogenesis of vasculitis in CTD is still unclear. The accumulation 
of immune complexes in the vasa nervorum initiates the leukocytoclastic reaction, 
which is characterized by segmental fibrinoid necrosis and transmural inflam-
matory cell infiltration. Vasculitis induces the occlusion of vasa nervorum at the 
Vasculitic neuropathy
 Mononeuropathy multiplex
 Asymmetrical polyneuropathy
 Distal symmetrical polyneuropathy
Distal axonal polyneuropathy
Compression neuropathy
Sensory neuronopathy
Trigeminal sensory neuropathy
Other types of neuropathies associated with connective tissue disease
 Acute demyelinating polyneuropathy
 Chronic demyelinating polyneuropathy
Table 1. 
Types of neuropathies associated with CTD (adapted from neuropathies in connective tissue disease/Richard K) [12].
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epineurial arteries and produces nerve infarction. Nerve infarcts typically lead to 
axonal degeneration [14]. Demyelination and conduction block may occur tran-
siently but are usually not a predominant or persistent finding [15]. The clinical and 
electrophysiological features of neuropathies correlate with the rapidity of onset 
of ischemia. Acute ischemia induces the development of mononeuropathy, while 
prolonged circulatory insufficiency is associated with chronic polyneuropathy. The 
compression-ischemic mechanism leads to the formation of tunnel syndromes [13, 
14, 16, 17]. The Peripheral Nerve Society task force has recently proposed a clas-
sification that categorizes vasculitic neuropathy into primary systemic vasculitides, 
secondary systemic vasculitides including CTD and nonsystemic or localized 
vasculitis on the basis of disease associations [18].
3.2 Autoimmune disorders
Patients with diffuse CTD may have IgG and IgM anticardiolipin antibodies 
in their serum, which are associated with severe signs of neural lesions, as dem-
onstrated by electromyogram [13]. Moreover, serum levels of anti-nerve growth 
factor (NGF) antibodies are greater than normal in 32.1% of patients with diffuse 
CTD. Increased serum levels of anti-NGF are associated with high disease activity 
and more severe nervous system involvement [13].
3.3 Metabolic disorder
Peripheral nervous system abnormalities in CTD are also explained by metabolic 
disorder secondary to aggressive therapy, multiorgan pathology and endocrine 
abnormalities in these patients. Metabolic disorder may induce a reaction of demy-
elization and axon dystrophy in severe cases [13].
4. Clinical practice guidelines of peripheral neuropathy in CTD
In CTD neuropathic symptoms often start gradually and then get worse. Deep 
proximal aching pain is the first sign in the affected limb. Burning pain in the 
cutaneous distribution of the affected nerve is frequent. Weakness and numbness 
usually appear over several hours to several days after the pain. The delay of the 
former symptoms is explained by the nerve infarction. On physical examination, 
most patients have pain and temperature sensory loss in the distribution of the 
affected nerve. A few patients have impairment of vibration and position sense. 
Hyporeflexia is also rare except in the ankles. In fact, tendon reflexes other than 
at the ankle are lost only if the femoral, musculocutaneous, or radial nerves are 
affected proximally [12, 18, 19]. The quantitative sensory testing (QST) is a tool 
to analyse the perception in response to external stimuli of controlled intensity. It 
has been used for the early diagnosis and follow-up of small fibre neuropathies. 
Although the QST is time-consuming and it is modified also in non-neuropathic 
pain as in rheumatoid arthritis and inflammatory myalgia, it cannot be taken 
alone as a conclusive demonstration of PN [20]. The QST is helpful to quantify the 
effects of treatments on allodynia and hyperalgesia and may reveal a differential 
efficacy of treatments on different pain components (grade A) [20]. According to 
EFNS international guidelines, to evaluate hyperalgesia in PN, it is recommended 
to use simple tools such as a brush and at least one high-intensity weighted pin-
prick or von Frey filament. The evaluation of pain in response to thermal stimuli 
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is best performed by using the thermotest which is recommended for pathophysi-
ological research or treatment trials. The DN4 may be a useful instrument for the 
daily diagnostic of PN in CTD [21].
5. Diagnosis and clinical results
In patient with multiorgan involvement and mononeuropathy multiplex, the 
diagnosis of vasculitic neuropathy is usually easy. However, the diagnosis may be 
more difficult in less typical presentations of CTD or when peripheral neuropathy is 
the unique manifestation of the disease. The diagnosis of peripheral neuropathy in 
CTD particularly in atypical situation is based first on clinical and physical exami-
nations. Electromyography confirms even an underlying axonal neuropathy. The 
most characteristic electromyographic finding in vasculitic neuropathy described in 
the previous series is axonal degeneration with multifocal distribution. The typical 
feature is a low sensory nerve and compound muscle action potential amplitudes in 
a non-length-dependent distribution with normal or minimally reduced conduction 
velocities [15, 17, 22, 23]. A partial conduction block is rare, and it is seen transiently 
and early in stage of nerve ischemia [12]. Laboratory tests may be helpful in estab-
lishing the presence of systemic vasculitis or identifying previously undiagnosed 
connective tissue disease. Evaluation of patients with suspected neuropathy in 
CTD should include liver and kidney function tests, erythrocyte sedimentation 
rate, urinalysis as well as a complete blood count. The choice of immunological test 
including rheumatoid factor, antinuclear antibody, cryoglobulins, antineutrophil 
cytoplasmic autoantibody and serum complement depends on the clinical pre-
sentation of the patient. Nerve biopsy may be helpful in demonstrating vasculitic 
process. A concomitant muscle specimen is useful to increase diagnostic yield 
because of the patchy distribution of vasculitic lesions [18].
6. Particularity of PN in each CTD
6.1 Peripheral neuropathy in Sjögren syndrome
Sjögren syndrome is a CTD more prevalent in women at the age of menopause. It 
is characterized by sicca syndrome and other extra-glandular symptoms. Peripheral 
nervous involvement in Sjögren syndrome (SS) is reported with variable frequency 
because of diverse methods for detection of neuropathy and may precede the onset 
of the disease or be the initial diagnostic clue [24]. The most common feature is 
symmetrical distal sensory neuropathy, autonomic neuropathy and trigeminal 
sensory neuropathy. Mononeuritis multiplex, chronic inflammatory demyelinating 
neuropathy and motor neuropathy are less common [8].
6.1.1 Ganglionopathies
Sensory ganglionopathy is characterized by an impairment of kinesthetic aware-
ness. Patients have the profound handicap of proprioceptive sense affecting larger 
joints. Electromyogram shows unelicitable sensory nerve action potentials, with 
preservation of compound motor action potentials [25]. When MRI is performed, 
it can reveal T2 hyperintensities limited to the gracile and cuneatus tracts of the 
dorsal spinal cord with sensory neuronopathies [26]. There are two mechanisms 
evoked in the pathogenesis of gangliopathies in SS. First, the cellular autoimmu-
nity, confirmed by the infiltration of mononuclear and predominantly T cells in 
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the dorsal root ganglia, is associated with cellular degeneration in the absence of 
vasculitis [25, 27, 28]. Second, recent studies have suggested that the presence of 
antibodies against the G-bodies, which are a subcellular aggregation of noncoding 
RNA intermediates and proteins, is associated to neuropathy [29, 30]. Moreover, 
It was reported that antineuronal antibodies were seen more frequently in Sjögren 
patients with severe peripheral neuropathy (PN) complications [25].
6.1.2 Small fibre neuropathies
Small fibre neuropathy is the most common PN manifestation of SS. It is a 
painful, sensory neuropathy affecting the nociceptive A-alpha and unmyelinated 
C-fibres. Small fibre neuropathy is reported with variable frequency. In the Hopkins 
Green Sjögren cohort, it was described as the most frequent manifestation [31]. The 
onset of small fibre neuropathy is usually subacute to chronic, occurring over weeks 
to months, although cases with hyperacute evolution of hours to days have been 
reported [27]. The cardinal clinical symptom of isolated small fibre neuropathy is an 
excruciating burning pain. The physical examination reveals a selective impairment 
in small-fibre modalities of pinprick and temperature, with relatively preserved 
vibratory sense and proprioception. The diagnosis of small fibre neuropathy is based 
on skin biopsy, which assesses the low density of intraepidermal nerve fibres [25, 32].
6.1.3 Sensorimotor polyneuropathies
The majority of studies reported that axonal polyneuropathies as the most 
frequent type of PN in SS. The onset of sensorimotor polyneuropathy is usually sub-
acute or chronic. The axonal sensory neuropathies are characterized by propriocep-
tive sensory loss and motor reflexes, and there are diminished sensory nerve action 
potentials in electromyogram [25]. The sensory symptoms, however, are gradually 
accompanied by muscle weakness in a distal, symmetrical distribution [32].
6.1.4 Multiple mononeuropathy
It is the transduction of vasculitic neuropathy, and it is very uncommon in SS 
reported in 0–5% in previous studies. It is usually associated with extra-glandular 
manifestations [25, 27, 33–35]. Patients with SS and presenting mononeuritis multiplex 
should be assessed for cryoglobulinemia polyclonal (types II and III) rather than mono-
clonal (type I) mainly when there is high-titer rheumatoid factor positivity or when 
there is disproportionate C4 hypocomplementemia, with normal levels of C3. When 
nerve biopsy is performed, it may show a lymphocytic or necrotizing vasculitis [32].
6.1.5 Cranial neuropathies
The most common cranial neuropathy in SS is the trigeminal neuropathy, which 
is usually progressive and can be bilateral and requires symptomatic treatment. 
Motor dysfunction of cranial nerves is less common, and the facial nerve is the most 
cranial nerve targeted. The acute onset of cranial neuropathy is due to vasculitic 
mechanism especially when associated with equally rapid development of multiple 
mononeuropathies in the extremities [25].
6.1.6 Demyelinating neuropathies
Demyelinating neuropathy is a rare manifestation of SS [32, 33]. Cases of 
chronic idiopathic demyelinating polyneuropathy have been the subject of case 
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reports in Sjögren patients but have not been substantially described in larger case 
series. The most common neurophysiologic finding in demyelinating neuropathies 
was demyelination of the motor nerves [36–38]. The onset of this neuropathy is 
subacute and characterized by severe proximal and distal weakness and proprio-
ceptive sensory deficit. Treatment with steroid and sometimes with intravenous 
immune globulins may be effective [32, 39].
6.1.7 Autonomic neuropathy
Autonomic neuropathy is the rarest type of peripheral nerve involvement in 
SS because it is usually underdiagnosed. The clinical manifestations of autonomic 
neuropathy will vary depending on the organs which are affected. Symptoms range 
from urinary symptoms to severe disabling postural hypotension [27, 32, 38]. In 
recent studies, autonomic dysfunction is associated with the severity of fatigue in 
patients with primary SS. However, no association was detected between autonomic 
dysfunction and exocrine function in these patients [32, 40].
6.2 Peripheral neuropathy in systemic erythematosus lupus
Systemic lupus erythematosus is a multisystem autoimmune disorder with 
a broad spectrum of clinical presentations as cutaneous, renal and articular 
manifestations (Figure 1). Affected patients typically have subacute or chronic 
distal symmetrical polyneuropathies with predominant sensory symptoms. Distal 
symmetrical axonal degeneration is the major feature of most cases, although other 
types of peripheral neuropathy have been described [12, 41]. Oomatia reported 
the subtypes of peripheral neuropathy (PN) attributable to SLE in a group of 82 
patients out of 2097 and detailed in Table 2 [42]. Other features such as Guillain-
Barré syndrome, plexopathy and autonomic neuropathy are very low in all series 
Figure 1. 
Butterfly rash in systemic lupus erythematosus.
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[41]. In recent data, small fibre neuropathy is more frequent in SLE, and the 
decreased intraepidermal nerve fibre density of unmyelinated fibres is a diagnostic 
test [42]. The mechanisms of peripheral neuropathy in SLE are unclear. Several 
factors have been reported particularly small-vessel vasculitis and lesions induced 
by autoimmune antibodies and immune complexes. In series, where nerve biopsy 
is performed, the anatomopathologic aspect was perivascular mononuclear cell 
infiltration and variable intimal thickening without necrotizing vasculitis. The 
presence of necrotizing vasculitis is possible and constitutes a prognostic factor of 
the disease [12, 41, 43]. Endoneurial mononuclear cell infiltration and increased 
class II antigen expression were also noticed [12, 43].
6.3 Peripheral neuropathy in systemic sclerosis
Systemic sclerosis is a rare connective tissue disease with a prevalence of 1 in 
10,000 [44]. It is characterized by symmetrical, widespread thickening of the skin 
(Figure 2) [45]. The prevalence of peripheral neuropathy is unknown with reported 
ranges in retrospective studies varying from 0.01 to 14% of patients [46, 47]. 
Vascular-dependent neuropathy is the principal mechanism inducing a distal 
symmetric, mainly sensory polyneuropathy as in other connective tissue diseases 
[13, 46, 47]. Cranial mononeuropathies can also occur, mainly the trigeminal 
nerve, leading to numbness and dysesthesias in the face. Rarely the seventh and 
ninth cranial neuropathies are affected [11]. The electrophysiological features are 
those of sensory axonopathy [11]. Rare cases of mononeuritis multiplex have been 
mentioned in the course of limited SSc (CREST: calcinosis, Raynaud’s phenomenon, 
oesophageal dysmotility, sclerodactyly, telangiectasia) and are due to a necrotizing 
vasculitis [11].
6.4 Peripheral neuropathy in mixed connective tissue disease
Mixed connective tissue disease is defined as the overlap of SLE, SSc and PM, 
with a high titer of extractable nuclear antigen and its ribonucleoprotein compo-
nent [48]. Mild distal axonal polyneuropathy was exceptionally reported in 2 of 
20 patients with mixed connective tissue disease, but there has not been a detailed 
study of the neuropathy or its treatment [48].
Type of peripheral neuropathy Frequency no. (%)
Axonal neuropathies 46 (56.1)
 Sensory axonal polyneuropathy 19 (23.2)
 Sensorimotor axonal polyneuropathy 21 (25.6)
 Mononeuritis multiplex 6 (7.3)
Small fibre neuropathies 14 (17.1)
Demyelinating polyneuropathies
 Acute inflammatory demyelinating polyneuropathy 1 (1.2)
 Sensory demyelinating polyneuropathy 1 (1.2)
Mixed axonal-demyelinating sensorimotor polyneuropathy 3 (3.6)
Plexopathy 1 (1.2)
Table 2. 
Type of peripheral neuropathy in SLE (adapted from peripheral neuropathies in systemic lupus erythematous/
Oomatia et al.) [42].
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6.5 Peripheral neuropathy in dermatomyositis and polymyositis
Nerve involvement in patients with DM is mediated through membrane attack 
complex (MAC) formation, leading to nerve injury. This entity called “neuromyo-
sitis” was first reported in 1890 [49]. Further studies showed a frequency of 7.5% in 
DM or PM patients with polyneuropathy [50]. Neuropathy due to DM is difficult to 
diagnose due to necessity of excluding other comorbid etiologic conditions and het-
erogeneity of muscular manifestations [49]. Nerve biopsy may reveal endothelial 
vascular injury, and immunohistochemical stains revealed increased expression of 
perivascular VEGF and demyelinization associated or not with inflammation [51].
7. Treatment of peripheral neuropathy in CTD
7.1 General approach
There are no treatment guidelines specific to each CTD. In general, the manage-
ment of PN is based on symptomatic treatment of pain as in other causes of neurop-
athies. Typically, patients with painful polyneuropathies respond to drugs known to 
be effective for neuropathic pain, including tricyclic antidepressants and a variety 
of antiepileptic drugs as gabapentin and pregabalin, which is preferred because of 
its better bioavailability [52]. Concerning the antidepressants, international guide-
lines provide the same level of recommendation for nonselective tricyclic antide-
pressants and serotonin-norepinephrine reuptake inhibitors (SNRIs). Most clinical 
trials showed that the efficacy of SNRIs is lower than that of tricyclic antidepres-
sants. However, tricyclic antidepressants have more side effects in elderly and are 
contraindicated in patients with glaucoma, prostate hypertrophy or some cardiac 
conduction disturbances. Venlafaxine is a SNRI who has shown efficacy in painful 
polyneuropathies of different origins [53]. In CTD, PN is mainly due to vasculitic 
Figure 2. 
Sclerosis of the face in systemic sclerosis.
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and immune abnormalities. So when vasculitic neuropathy is diagnosed, cortico-
steroids should be promptly introduced to recover sensory and motor deficits [3]. 
Most authors recommend starting oral prednisone at high dose of 1 mg/kg per day. 
In severe cases, intravenous pulses of methylprednisolone of one 1 g for 3–5 days 
might be appropriate for initial treatment. This treatment should be maintained 
during the subacute phase, and after 6 to 8 weeks, the treatment should be tapered 
progressively. Immunosuppressant therapy is associated to corticosteroids in severe 
forms of vasculitic neuropathy or in systemic vasculitic PN. Cyclophosphamide 
seems to be the most effective drug for induction of remission and improvement of 
survival in non-viral systemic vasculitides [18]. Most patients need 3–12 months of 
cyclophosphamide induction therapy before they can be switched to a maintenance 
immunosuppressant [54]. Immunosuppressant used as a maintenance therapy is 
azathioprine, methotrexate and mycophenolate mofetil [55]. Intravenous immuno-
globulin is a safe treatment used in serious systemic PN with clinical benefit [18].
7.2 Particularities of treatment in each CTD
Therapeutic strategies of small fibre neuropathy in SS are still unclear. 
Carbamazepine is generally the first-line agent for trigeminal neuralgia. The use 
PNS manifestation First-line treatment approach Treatment of 
refractory cases
Polyneuropathy Neurotrophic agents (tricyclic antidepressants, 
SNRI (duloxetine, venlafaxine), anticonvulsants 
(gabapentin, pregabalin)) (glucocorticoids  
(1 mg/kg/day of prednisone equivalent))
Severe forms: immunosuppressants (azathioprine, 
mycophenolate mofetil, cyclophosphamide)
Carbamazepine
High-dose IVIG
PEX
Rituximab
Mononeuropathy single/
multiple
Systemic glucocorticoids (1–2 mg/kg/
day of prednisone equivalent or pulses of 
methylprednisolone 500/1000 mg for 3–5 days with 
long-term dosage reduction)
IV
Cyclophosphamide
Rituximab, IVIG, PEX
Mycophenolate mofetil
Azathioprine
Small fibre neuropathy Neurotrophic agents (tricyclic antidepressants,
SNRI (duloxetine, venlafaxine), anticonvulsants
(gabapentin, pregabalin)), topical anaesthetics
Analgesics
Immunosuppressants
IVIG
Psychological support
Acute inflammatory 
demyelinating 
polyradiculoneuropathy 
(GBS)
High-dose IVIG
PEX
Cardiorespiratory supporting measures
Glucocorticoids (1 mg/
kg/day of prednisone 
1000 mg for 3 days)
Equivalent or pulses of 
methylprednisolone 
and 
immunosuppressants 
– cyclophosphamide
Cranial neuropathy Glucocorticoids (1 mg/kg/day of prednisone 
equivalent) with long-term dosage reduction
Spontaneous recovery possible for oculomotor 
involvement
Cyclophosphamide
immunosuppressants 
as maintenance 
treatment
PNS: peripheral nervous system; SNRI: serotonin-norepinephrine reuptake inhibitors; IVIG: intravenous 
immunoglobulins; PEX: plasma exchange; GBS: Guillain Barré Syndrom.
Table 3. 
Treatment options available for peripheral nervous system involvement in patients with SLE (adapted from 
PNS involvement in SLE/A. Bortoluzzi et al.) [60].
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of other antiepileptic agents such as gabapentin should be prescribed with slow 
titration to minimize its side effects particularly over somnolence and fatigue. 
The duration of therapeutic trial should be at least 3 months. The secondary 
amine tricyclic antidepressants such as nortriptyline and desipramine have fewer 
anticholinergic side effects and a proven efficacy in neuropathic pain, and so 
they may be slowly prescribed in patients with SS. The use of new immunosup-
pressant agents mainly monoclonal antibody directed against CD20 antigen on 
B cells as rituximab and the tumour necrosis factor (TNF)-alpha inhibitors such 
as adalimumab has been reported to be efficient in the small fibre neuropathies 
occurring in SS [25]. The management of axonal polyneuropathy is based on a 
symptomatic treatment; corticosteroids and immunosuppressors are discussed 
in the case of motor neuropathy with rapid progression [25]. In the case of 
multiple mononeuropathy, the presence of vasculitis is associated with a good 
response to immunosuppressive therapy [34]. There is evidence supporting the 
use of immunoglobulin therapy in Sjögren-associated sensorimotor and non-
ataxic sensory neuropathy from retrospective and observational cohorts and case 
reports [56, 57].
In SLE, there are no clear guidelines on the treatment of peripheral neuropathy. 
Induction treatments with glucocorticoids with or without immunosuppressant 
agents are indicated in the situation of active vasculitic neuropathy [58]. In the case 
of necrotizing vasculitis, treatment with plasmapheresis, steroids and immunosup-
pressant has led to improvement [59, 60]. The definitions of response to treatment 
are variable between studies. Overall, the rate of global response (complete or 
partial) is more than 50% [41] (Table 3).
In SSc, there is not enough data regarding the response of scleroderma-associated 
neuropathy to immunosuppression [11, 61]. However, this therapy seems to be 
effective in mononeuritis multiplex and sensorimotor polyneuropathy with inflam-
matory process [11]. In DM/PM the treatment of PN is based on corticosteroids and 
immunosuppressant agents depending on the severity of the clinic presentation [51].
PNS, peripheral nervous system; SNRI, serotonin-norepinephrine reuptake 
inhibitors; IVIG, intravenous immunoglobulins; PEX, plasma exchange; GBS, 
Guillain-Barré syndrome.
8. Conclusion
8.1 Final considerations
PN is one of the possible neurologic manifestations encountered by physi-
cians in CTD. Coexistence of both conditions is explained by immune-mediated 
factors particularly a vasculitis of peripheral nerve. Therefore, it is important to 
take a detailed medical history and examination and then adequate investigations 
to assess for an underlying systemic autoimmune diseases that may be associated 
with the neuropathy. Pure sensory and sensorimotor neuropathies are the most 
common PN features in these disorders. Acute to subacutely evolving multifocal 
or asymmetric neuropathy suggests a vasculitic cause. This situation constitutes a 
prognostic factor of the disease and requires prompt treatment with steroids and 
immunosuppressant agents. The treatment of PN in CTD progresses in three fronts: 
first, to identify the type of PN through the medical history and physical exam; 
second, to precise the pathogenic mechanism of neuropathy via clinical presenta-
tion, electromyographic data and in unclear situation the nerve biopsy and finally, 
the efficient control of pain. Corticosteroids remain the mainstay of treatment for 
vasculitic neuropathy in CTD.
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8.2 Futures directions
Although much is known about the PN in CTD, particularly its pathogenesis and 
its clinical aspects, further experience needs to be gained especially in the treatment 
with prospective trials to identify indications and precise efficacy for cytotoxic 
agents, intravenous immunoglobulin, plasma exchange and new biological drugs. 
In future, we need also further studies to precise clear guidelines to diagnose PN 
related to CTD such as more specific features in the electromyogram and neuro-
muscular biopsy. Moreover, in the treatment approach of PN in CTD, we need 
further researches to identify curative drugs targeting the pathogenesis pathways 
rather than the symptomatic and the previous conventional therapy.
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